Heart disease: Semaglutide may reduce risk by up to 20% in 6 months
Written by Jessica Freeborn on May 18, 2025 — Fact checked by Amanda Ward
Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images Preventing major adverse cardiovascular events like heart attacks and strokes is better than treating them.
Research about potential prevention strategies, including the use of semaglutide, a drug used to treat type 2 diabetes and aid weight loss, is ongoing.
Results of a secondary analysis found that semaglutide may help decrease the risk of death from any cause, death from cardiovascular causes, combined heart failure outcomes, and major adverse cardiovascular events after just six months of receiving semaglutide.
A recent secondary analysis of a study shared at the 32nd European Congress on Obesity helps to further demonstrate that the benefits of semaglutide begin early. It builds on the findings from a study published in 2023 in the New England Journal of Medicine, which found that weekly injections of semaglutide helped to decrease the risk of stroke, heart attack, or death from cardiovascular causes.
At just three months, before dose titration was over, participants on semaglutide had a noted decreased risk for stroke, heart attack, or cardiovascular death, with additional benefits at six months.
The findings suggest an early advantage of taking semaglutide for people with cardiovascular disease who are overweight or obese.
Semaglutide assists with weight management, and it may also minimize the risk of severe cardiovascular outcomes, according to the original study this secondary analysis is based on.
This study included 17,604 participants who were overweight or obese and already had cardiovascular disease. About half of the participants received semaglutide while the other half received the placebo.
The researchers found that participants who received semaglutide had a 20% decreased risk of experiencing non-fatal heart attacks, non-fatal strokes, or death from cardiovascular causes. The average follow-up time with participants was 39.8 months, and the average time participants took semaglutide was 34.2 months.
This secondary analysis focused on heart health in the first six months after participant randomization. The results suggest that the cardiovascular benefits of semaglutide could begin fairly early on.
At three months, researchers found that participants who received semaglutide had a decreased risk for major adverse cardiovascular events (MACE), which included non-fatal heart attack, non-fatal stroke, or cardiovascular death.
These findings occurred even before there was significant weight loss among participants in the semaglutide group and even before participants had reached the full dose of semaglutide.
Typically, people start on a lower dose of semaglutide and build up to receiving a 2.4 mg dose of semaglutide. The titration timeframe usually lasts sixteen weeks, and researchers of the 2023 study followed this typical timeline.
At four weeks, semaglutide participants had an average difference in body weight of 1.1% lower than those in the placebo group. At 12 weeks, the average weight difference was 3.6% lower in the semaglutide group compared to the placebo group.
At six months, researchers observed similar outcomes for MACE. They also found the semaglutide group had a decreased risk for death from any cause, death from cardiovascular causes, and the measured heart failure composite, which included having an urgent medical visit or hospitalization from heart failure and death from cardiovascular causes.
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the study's results:
'The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81).'
'While the underlying mechanisms of semaglutide's early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes,' he told Medical News Today.
The full secondary analysis is unavailable, so it is not entirely clear what the research limitations are. This initial report lacked some information that will become available at the time of full study publication.
'Additional analyses of the early MACE separation for semaglutide versus placebo by individual MACE components, additional clinical outcomes, patient subgroups, and other parameters changing during the early post-randomisation stages of the trial will be provided,' the authors note.
Thus, it's not entirely clear what the outcomes are for some individual endpoints at this time, and this will be clearer when the full study is available.
The secondary analysis would also carry similar limitations to the original study. For example, the original research focused on people who already had cardiovascular disease and did not have diabetes, and all participants were at least 45 years old. The results could be different in other groups with other criteria in place.
Less than 30% of participants were women, and there was a relatively low number of Black participants. Thus, the sample did not represent the global population.
It may be beneficial to verify the findings of this analysis in other study samples. The authors of the secondary analysis also note that research can further focus on why semaglutide produced the effects they observed.
These analysis results suggest the benefits of semaglutide, even in the short term, regarding cardiovascular outcomes in at-risk individuals. This research could help expand the prevention of deaths related to cardiovascular problems.
Cheng-Han Chen, MD, a board certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA, who was also not involved in the study, said:
'This study suggests that patients overall receive a benefit to cardiovascular health with semaglutide early in their treatment course even before losing significant body weight. As there are a certain proportion of patients who do not actually lose significant weight with semaglutide treatment, it may potentially be worthwhile to keep these patients on therapy for this reason despite not losing weight.'
'This study gives us more information on the timing of the cardiovascular benefit of semaglutide. This will help us to design treatment programs for our patients and provides a benchmark for comparison of future therapies,' he told MNT.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Woman diagnosed with common UTI...now she's had to have all 4 limbs amputated because of little-known infection complication
A mother-of-two has urged people to learn the warning signs of sepsis after losing four of her limbs following a common infection. Kim Smith, 63, from Milton Keynes, was left with blackened legs, feet and hands that needed to be amputated after a life-threatening ordeal left her in a coma for months. In 2018, Mrs Smith was on holiday in Alicante, Spain with her husband Steve when she developed a urinary tract infection (UTI). A UTI is a common infection where bacteria infiltrates parts of the body like the bladder, kidneys and urethra, causing a burning sensation when urinating. Familiar with the common symptoms of a UTI—including needing to urinate more often and lower abdominal pain—Mrs Smith went to the doctors who prescribed her antibiotics. But the pharmacist did not have her prescription available for collection that day, so the couple returned to their hotel, where Mrs Smith's condition quickly deteriorated. 'I woke up at 4am and I thought I was going to die,' she said in a TikTok video that has so far garnered over 793,000 views. 'I had severe breathlessness, slurred speech and confusion. I was really really cold. I had a fever and I was shivering like mad,' she added. Her husband rushed her to the hospital where she was diagnosed with severe sepsis and put into a medically induced coma on November 29th. Sepsis is a life-threatening reaction to an infection, which occurs when the body's immune system overreacts to an infection—like a UTI—and attacks its own tissue and organs. By the next day, her hands had already turned purple. 'Spain had told my daughters that I had black digits, that's fingers and toes', Mrs Smith recalled. 'My arms were black up to [my elbows]'. Eventually, after six weeks on life support, Mrs Smith was flown back to the UK, to Milton Keynes University Hospital, via air ambulance. There, after three weeks back in the UK, Mrs Smith was gradually brought out from her coma. 'When I woke up, I could actually see that my hands and legs were black, so I knew that they would have to be amputated', she remembers. Mrs Smith then underwent life-changing surgery to amputate her hands and legs above the knee. Once she recovered from the quadruple amputation, the grandmother spent 12 weeks in physical rehabilitation, where she regained her strength and learnt to live without her limbs. Now, Mrs Smith wants to raise awareness for the little-known risk associated with common UTIs. 'I want to tell you, if you need to go pee, go pee. Don't hold it—that could cause you to get an infection and that could develop into sepsis,' she said. 'The symptoms are severe breathlessness, slurred speech and confusion-I had that-I didn't pass much urine that day and I had a fever but I was really cold.' 'If you get anything like that, if you feel unusually unwell and you know something is not right, please please please advocate for yourself,' Mrs Smith urged her followers. 'Tell [doctors] something is not right and ask them to test you for sepsis. 'Ask for a second opinion if you have to. Do not leave if you feel something is wrong.' UTIs affect the urinary tract, which includes the bladder, the urethra and the kidneys. According to the NHS, common symptoms include pain or a burning sensation when peeing, needing to pass urine more often than usual, and cloudy looking urine––which can also be a sign of dehydration. Some people may also experience lower abdominal or back pain, as well as a high temperature, chills or and a really low temperature below 36C. These more severe symptoms could indicate a kidney infection, which can be serious if left untreated, developing into life-threatening sepsis. Up to 1.7million people in the UK suffer from recurrent UTIs—classed as three or more infections a year. Around half of all women will experience a UTI in their life time. According to the World Health Organisation (WHO), sepsis kills 11 million people globally each year, while in the UK the infection claims around 48,000 lives. People who suffer septic shock can develop small blood clots, which cut-off life-giving oxygen flow to the extremities. The tissue then begins to die, and the skin turns black. However, if there is still enough healthy tissue, doctors may try to first remove the dead tissue—known as debriding. If this treatment doesn't work, amputation is the next step. UTIs are one of the most common causes of sepsis, dubbed the 'silent killer' because its symptoms can overlap with other conditions like the flu. However, as Mrs Smith warns, knowing the symptoms of sepsis could save your life. Tell-tale signs of sepsis in adults include appearing confused, slurred speech or not making sense, blue, grey or blotchy skin and difficulty breathing. According to the NHS, a rash that doesn't fade when your roll a glass over it could be a tell-tale sign of the condition, as well as having a pale and blotchy appearance that is cold and clammy to the touch. Sepsis affected skin may also develop pinprick bruises or large purple areas that can also turn blue, a sign the body is not getting enough oxygen. Producing less urine than usual, for example not urinating for an entire day, is another potential sign of serious sepsis. This is in part because a decrease in blood pressure caused by sepsis, as well as an increased risk of blood clots, can reduce blood supply to organs like the kidneys, which produce urine, impacting their function. As the kidneys can be some of the first organs to start showing signs of reduced function due to sepsis, reduced urine production is considered a potential sign of the condition. The NHS advises anyone who experiences these symptoms to call 999 or go to A&E immediately.
Daily Mail
an hour ago
- Daily Mail
Welcome to the 'National Health State': Half of all public spending will go on NHS by the end of the decade despite alarm at dire productivity... and bosses STILL want more
The growing stranglehold of the NHS over public spending was underlined today as Brits digest Rachel Reeves ' plans. A respected think-tank has insisted the UK is turning into the 'National Health State' after another major funding boost. In an extraordinary spree, the Chancellor allocated an extra £29billion per year and more cash for capital investment. Ruth Curtice, chief executive of the Resolution Foundation, pointed out that amounted to 90 per cent of Labour 's extra public spending. She cautioned that continued a 'trend that is seeing the British state morph into a National Health State, with half of public service spending set to be on health by the end of the decade'. The latest huge cash injection comes despite concerns about progress in improving productivity in the NHS. Health service chiefs have also been warning that more money will be needed, with nurses already balloting for industrial action over an inflation-busting 3.6 pr cent pay offer. Matthew Taylor, of the NHS Confederation, which represents health organisations, said: 'Difficult decisions will still need to be made as this additional £29billion won't be enough to cover increasing costs of new treatments, with staff pay likely to account for a large proportion of it. 'On its own, this won't guarantee that waiting time targets are met.' Sir Jim Mackey, chief executive of NHS England, told the NHS ConfedExpo conference in Manchester that the health service has done 'really well relative to other parts of the public service'. But he added: 'We all know it's never enough because of the scale of advancement, all the ambition, the day-to-day cost pressures... but I think everyone's starting to accept and understand we've got what the country can afford to give us. 'We really need to get better value for that money – it is broadly the equivalent of the GDP of Portugal, so it's a huge amount.' Ms Curtice said defence was another winner from the Spending Review, receiving a significant increase in capital spending while other departments saw an overall £3.6billion real-terms cut in investment. The Institute for Fiscal Studies (IFS) has made similar arguments about 'substantial' investment in the NHS and defence coming at the expense of other departments, although the think tank's director Paul Johnson warned the money may not be enough. He said: 'Aiming to get back to meeting the NHS 18-week target for hospital waiting times within this Parliament is enormously ambitious – an NHS funding settlement below the long-run average might not measure up. 'And on defence, it's entirely possible that an increase in the Nato spending target will mean that maintaining defence spending at 2.6% of GDP no longer cuts the mustard.' Ms Curtice added that low and middle-income families had also done well out of the spending review 'after two rounds of painful tax rises and welfare cuts', with the poorest fifth of families benefiting from an average of £1,700 in extra spending on schools, hospitals and the police. She warned that, without economic growth, another round of tax rises was likely to come in the autumn as the Chancellor seeks to balance the books. She said: 'The extra money in this spending review has already been accounted for in the last forecast. 'But a weaker economic outlook and the unfunded changes to winter fuel payments mean the Chancellor will likely need to look again at tax rises in the autumn.' Ms Reeves insisted she would not have to raise taxes to cover her spending review - but stopped short of ruling them out. She told GB News: 'Every penny of this is funded through the tax increases and the changes to the fiscal rules that we set out last autumn.'
The Independent
an hour ago
- The Independent
Urgent warning over ‘unsafe' American sweets with cancer risks
British consumers are being warned against purchasing Jolly Rancher sweets due to potential cancer risks, according to the Food Standards Agency (FSA). The popular candies contain mineral oils, food additives that, when consumed regularly over time, may pose health risks, the FSA stated. These chemical compounds, including mineral oil aromatic hydrocarbons (Moah) and mineral oil saturated hydrocarbons (Mosh), are added to confectionery items to prevent stickiness and create a glossy appearance. However, their use does not comply with UK law. Hershey, the US producer that owns the Jolly Rancher brand, has been collaborating with the FSA to remove all Jolly Rancher products from the UK market since 2024. Despite these efforts, some British businesses continue to import the sweets, the agency noted. The affected products include Jolly Rancher Hard Candy, " Misfits" Gummies, Hard Candy Fruity 2 in 1, and Berry Gummies, the FSA confirmed. Consumers are advised to avoid these products to mitigate potential health risks. A food alert published by the FSA on Wednesday said: 'Consumption of the affected sweets is of toxicological concern, especially in younger age groups and where consumers eat a lot of the products or eat them regularly. 'Moah can cause damage to DNA and has the potential to increase the risk of cancer, particularly if consumed in high quantities over a prolonged period of time. Moah is a genotoxic carcinogen, therefore no exposure is without risk to human health.' It added: 'If you have bought any of the above products, do not eat them. 'Instead, dispose of them at home. If you are concerned, notify your Trading Standards department or environmental health department in the local authority you purchased it. 'For consumers, don't buy them, and if you've eaten these products, there should be no immediate cause for concern, as food safety risk is low, but don't eat any more.' The agency has also urged UK retailers and food businesses to cease all imports and sales of the candy brand, and asked enforcement authorities to ensure the products are removed from the shelves. The FSA said: 'Food businesses who import these products are advised to discontinue import and distribution of products. 'Food businesses selling these products in the UK are advised to immediately stop sales, undertake product withdrawals and where there have been retail sales, to undertake product recalls. 'The Hershey Company, who is the brand owner, has taken action to remove these products from the UK market. 'We are asking enforcement authorities to make immediate contact with businesses who may have been supplied with or received the affected products, and to take action to ensure that the non-compliant and potentially unsafe products are withdrawn from the market and where sold at retail, recalled. 'We are also asking the local authorities to inform the FSA of product recall and withdrawal actions.'
